Joerg Neermann Buys Shares of IMUX
Joerg Neermann acquired 25,370 shares of IMUX on June 29, 2026.
Key Points
- Joerg Neermann purchased 25,370 shares of IMUX on June 29, 2026.
- IMUX shares traded near $15.30 on Tuesday, with various insiders also buying.
- Analysts maintained a 'buy' rating, with price targets up to $27.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Joerg Neermann recently purchased 25,370 shares of IMUX on June 29, 2026. This insider buying activity occurred as shares of IMUX traded near $15.30 on Tuesday. The transaction wasn't planned under a Rule 10b5-1 plan, indicating a direct acquisition.
Insider Buying and Selling at Immunic, Inc.
Several insiders at IMUX made notable purchases on June 29, 2026. Jon Congleton bought 50,740 shares, while Jason Tardio, the President and COO, acquired 253,000 shares. The Chief Financial Officer, Glenn Whaley, also purchased 120,000 shares. Daniel Vitt and Tamar Howson each bought 445,000 and 25,370 shares, respectively.
Other Institutional Activity in IMUX
Among institutional investors, Aberdeen Group PLC and BVF Inc/IL significantly reduced their holdings, each cutting their stakes by 90%. Aberdeen Group PLC now holds 824,394 shares valued at about $9.15 million, while BVF Inc/IL has 765,297 shares worth approximately $8.49 million. Avidity Partners Management LP also trimmed its position by 85.7%, leaving it with 669,941 shares valued at $7.44 million. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. opened new positions with 513,832 and 450,000 shares, respectively.
Analysts Set New Price Targets
On May 22, 2026, B. Riley Securities maintained a 'buy' rating on IMUX, setting a price target of $27. HC Wainwright & Co. also reiterated its 'buy' rating with a $22 target on April 30. Earlier, Stifel initiated coverage with a 'buy' rating and a $2.5 target on April 17. Overall, the consensus remains positive, with multiple firms maintaining 'buy' ratings.
Bottom Line
Joerg Neermann's purchase of IMUX shares highlights ongoing interest from insiders at the company. With shares trading near $15.30, this buying activity suggests confidence in IMUX's prospects. Institutional movements show both reductions and new positions, reflecting varied strategies among investors. Analyst ratings remain supportive, with targets reaching up to $27, indicating optimism about the company's future performance.
Get Immunic, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMUX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.